Kelyniam Swings to Operating Profit as Nine-Month Revenue Jumps 35%
Summary
Kelyniam reported nine-month 2026 revenue of $2,954,087, up 35% from $2,186,491 a year earlier, with gross profit up 41% to $2,383,632. The company swung to operating income of $244,509 from a prior-year operating loss of $(162,373) — its first return to profitability in the period. Management credits the Fusion BCP-PEEK implant launch and CustomizedBone unit sales that more than doubled year over year. For a micro-cap trading near $0.10, a swing to operating profit on roughly $3M of nine-month revenue is a meaningful fundamental shift, though the figures are unaudited and the full Q3 detail, including cash flow, is only posted on the company's website rather than filed with a full financial statement. Watch whether the operating profit holds in Q4 and whether the Fusion launch sustains the unit growth.
At the time of this announcement, KLYG was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $5M. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.